University Of Maryland, Baltimore

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1807-01-01

Employees: 7.3K

Market Cap: -

Website: http://www.umaryland.edu

Clinical Trials

2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Calaspargase pegol-mknl

First Posted Date: 2021-07-08

Last Posted Date: 2024-03-18

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 6

Registration Number: NCT04953780

Locations: 🇺🇸
Greenebaum Cancer Center, University of Maryland Medical Systems, Baltimore, Maryland, United States

2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

Recruiting

Conditions: oGVHD
Dry Eye Disease

Interventions: Diagnostic Test: The standard care exam and biological specimens' collection

First Posted Date: 2021-07-01

Last Posted Date: 2024-08-02

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 150

Registration Number: NCT04946721

Locations: 🇺🇸
Geenebaum Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, United States

Clinical Decision Support Tool for Vancomycin Dosing in Children

Not Applicable

Active, not recruiting

Conditions: Vancomycin
Gram-Positive Bacterial Infections
Pharmacodynamics
Pharmacokinetics

Interventions: Device: Computer Decision Support Tool Intervention Group
Other: Matched Historical Controls

First Posted Date: 2021-06-03

Last Posted Date: 2024-12-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 75

Registration Number: NCT04911270

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone

First Posted Date: 2021-05-21

Last Posted Date: 2024-03-18

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 10

Registration Number: NCT04896658

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

Impact of Counseling and Education on Opioid Consumption After ACL Reconstruction

Not Applicable

Active, not recruiting

Conditions: Pain, Postoperative
Opioid Use

Interventions: Behavioral: Perioperative Pain Management Education and Counseling

First Posted Date: 2021-05-13

Last Posted Date: 2024-11-29

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 80

Registration Number: NCT04885231

Locations: 🇺🇸
University of Maryland Rehabilitation and Orthopaedic Institute, Baltimore, Maryland, United States

Heterotopic Ossification Prophylaxis

Not Applicable

Completed

Conditions: Acetabular Fracture
Heterotopic Ossification

Interventions: Procedure: External Beam Radiation (XRT)
Procedure: Debridement

First Posted Date: 2021-04-30

Last Posted Date: 2024-12-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 117

Registration Number: NCT04867278

Locations: 🇺🇸
University of Maryland, Shock Trauma Center, Baltimore, Maryland, United States

Malawi International Center of Excellence in Malaria Research School-based Cohort

Completed

Conditions: Malaria,Falciparum
Anemia
Malaria

Interventions: Other: Screening and treatment

First Posted Date: 2021-04-26

Last Posted Date: 2021-04-26

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 786

Registration Number: NCT04858087

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

Phase 1

Recruiting

Conditions: Virtual Reality
Pain
Placebo
Temporomandibular Disorder

Interventions: Behavioral: Active Virtual Reality
Behavioral: sham Virtual Reality
Other: No Intervention
Other: Natural history
Other: Saline
Drug: Naloxone

First Posted Date: 2021-04-20

Last Posted Date: 2024-05-23

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 259

Registration Number: NCT04851301

Locations: 🇺🇸
Luana Colloca, Baltimore, Maryland, United States

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

Phase 1

Withdrawn

Conditions: Hepatitis B

Interventions: Drug: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]

First Posted Date: 2021-04-14

Last Posted Date: 2022-07-22

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT04843852

Locations: 🇺🇸
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸
Dr Sang V Tran Internal Medicine Practice, Falls Church, Virginia, United States

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Phase 2

Active, not recruiting

Conditions: Mixed Phenotype Acute Leukemia (MPAL)
Measurable Residual Disease (MRD)

Interventions: Drug: BLINCYTO (Blinatumomab)

First Posted Date: 2021-04-01

Last Posted Date: 2024-08-02

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 2

Registration Number: NCT04827745

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy